Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata) on February 24, 2010. The report addresses a corporate governance change regarding the appointment of interim financial leadership.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel appointments.
Material Changes
On February 24, 2010, the Board of Directors appointed Cameron Lawrence, the Company's current Director of Financial Reporting, as the interim Principal Financial Officer, Principal Accounting Officer, and Treasurer. Mr. Lawrence will assume these financial management functions until a permanent Chief Financial Officer is named. His existing employment agreement and amending agreement remain unchanged and in full force.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks or contingencies beyond the standard disclosure of the officer appointment. No unusual items were reported.
Investor Verification Checklist
- Verify the timeline for the appointment of a permanent Chief Financial Officer.
- Review the attached Employment Agreement (Exhibit 10.1) and Amending Agreement (Exhibit 10.2) for any potential compensation implications not detailed in the summary.
- Confirm the current status of the company's financial reporting capabilities under interim leadership.